上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2026 , Vol. 46 >Issue 2: 256 - 264

DOI: https://doi.org/10.3969/j.issn.1674-8115.2026.02.016

短篇论著

肌萎缩侧索硬化相关基因致痉挛性截瘫表型：临床、影像及遗传学分析

  • 程先茹 ,
  • 曹煜雯 ,
  • 田沃土 ,
  • 曹立
展开
  • 1.安徽医科大学附属宿州医院神经内科，宿州 234000
    2.上海交通大学医学院附属第六人民医院神经内科，上海市神经系统罕见疾病生物样本库和精准诊断专业技术服务平台，上海 200233
    3.上海市第六人民医院海口骨科与糖尿病医院脑病中心，海口 570311
曹 立，主任医师，博士；电子信箱：caoli2000@yeah.net。

收稿日期: 2025-10-16

  录用日期: 2025-11-21

  网络出版日期: 2026-02-28

基金资助

国家自然科学基金(82371255,82201398,82071258);上海市优秀学术带头人项目(23XD1402500);上海市科技创新行动计划(23DZ2291500);上海市卫生健康领军人才(2022LJ011);医企融合创新成果转化专项(SHDC2022CRD037);上海市“医苑新星”青年医学人才培养资助计划青年医学人才类——专科项目[SHWSRS(2025)_071];上海市第六人民医院院级探索性临床研究项目(ynts202507);上海市卫生健康委员会卫生行业临床研究专项青年项目(151)

收起

Spastic paraplegia phenotypes associated with amyotrophic lateral sclerosis-related genes: clinical, imaging and genetic analysis

  • Cheng Xianru ,
  • Cao Yuwen ,
  • Tian Wotu ,
  • Cao Li
Expand
  • 1.Department of Neurology, Suzhou Hospital of Anhui Medical University, Suzhou 234000, China
    2.Department of Neurology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Neurological Rare Disease Biobank and Precision Diagnostic Technical Service Platform, Shanghai 200233, China
    3.Neurological Disorder Center, Haikou Orthopedic and Diabetes Hospital of Shanghai Sixth People's Hospital, Haikou 570311, China
Cao Li, E-mail: caoli2000@yeah.net.

Received date: 2025-10-16

  Accepted date: 2025-11-21

  Online published: 2026-02-28

Supported by

National Natural Science Foundation of China(82371255,82201398,82071258);Program for Shanghai Outstanding Academic Leaders(23XD1402500);Shanghai Science and Technology Innovation Action Plan(23DZ2291500);Program for Outstanding Medical Academic Leader of Shanghai(2022LJ011);Training Program for Research Physicians of Innovative Translational Ability(SHDC2022CRD037);Shanghai "Rising Stars of Medical Talents" Youth Development Program Youth Medical Talents-Specialist Program [SHWSRS(2025)_071];Exploratory Clinical Research Project of Shanghai Sixth People's Hospital(ynts202507);Shanghai Municipal Health Commission Clinical Research Youth Foundation(151)

Fold

摘要

目的·探析由肌萎缩侧索硬化（amyotrophic lateral sclerosis，ALS）相关基因所致的痉挛性截瘫（spastic paraplegia，SPG）表型的临床、影像和遗传学特征。方法·对2017年4月—2025年9月，上海交通大学医学院附属第六人民医院神经内科收治的5例由ALS相关基因所致SPG的家系进行详细的病史采集与影像学检查，并进行Sanger测序、家系共分离验证及表型分析。结果·5例先证者（男∶女=3∶2）平均发病年龄为（18.4±21.7）岁（1~51岁），平均病程为（12.8±13.3）年（3~33年）。体格检查提示，下肢肌张力增高（5/5）、下肢腱反射亢进（5/5）、髌阵挛（2/5）、踝阵挛（4/5）、下肢病理征阳性（4/5）、足畸形（2/5）。头颅MRI检查提示，2例患者存在异常，分别为例1的小脑和颈髓萎缩、例2的胼胝体压部出现少许异常信号。周围神经电生理检查提示，1例患者双下肢可见少量自发电位，且运动诱发电位显示中枢性损害。基因检测在5例患者中共检出肌萎缩侧索硬化2（amyotrophic lateral sclerosis 2，ALS2）、含缬酪肽蛋白（valosin-containing protein，VCP）、肌萎缩侧索硬化4（senataxin，SETX）、丝氨酸/苏氨酸蛋白激酶NEK1（never in mitosis gene A-related kinase 1，NEK1）等4个不同基因的致病性变异，其中新发现了ALS2基因的c.3527T>C（p.Met1176Thr）和c.1732T>C（p.Ser578Pro）2个变异。结论·分析了ALS相关基因所致的SPG患者的临床异质性和遗传学特征，为准确诊断和深入理解此类疾病提供临床依据。

关键词： 痉挛性截瘫; 肌萎缩侧索硬化; 肌萎缩侧索硬化2（ALS2）; 含缬酪肽蛋白（VCP）; 肌萎缩侧索硬化4（SETX）; 丝氨酸/苏氨酸蛋白激酶NEK1（NEK1）

本文引用格式

程先茹 , 曹煜雯 , 田沃土 , 曹立 . 肌萎缩侧索硬化相关基因致痉挛性截瘫表型：临床、影像及遗传学分析[J]. 上海交通大学学报（医学版）, 2026 , 46(2) : 256 -264 . DOI: 10.3969/j.issn.1674-8115.2026.02.016

Abstract

Objective ·To analyze the clinical, imaging, and genetic characteristics of spastic paraplegia (SPG) phenotypes caused by amyotrophic lateral sclerosis (ALS)-related genes. Methods ·A total of 5 pedigrees with SPG caused by ALS-related genes, admitted to the Department of Neurology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, from April 2017 to September 2025, were included in the study. Detailed medical histories and imaging examinations were collected, and Sanger sequencing, family co-segregation verification, and phenotype analyses were performed. Results ·Among the 5 probands, the male-to-female ratio was 3:2. The average age at onset was (18.4±21.7) years (ranging from 1 to 51 years), and the average disease duration was (12.8±13.3) years (ranging from 3 to 33 years). Physical examination revealed increased muscle tone in the lower extremities in all patients (5/5), hyperreflexia in the lower extremities (5/5), patellar clonus in 2 patients (2/5), ankle clonus in 4 patients (4/5), positive pathological signs in the lower extremities in 4 patients (4/5), and foot deformities in 2 patients (2/5). Brain MRI examinations detected abnormalities in 2 patients, specifically cerebellar and cervical spinal cord atrophy in case 1, and a small number of abnormal signals in the splenium of the corpus callosum in case 2. Peripheral nerve electrophysiological examinations indicated that a small number of spontaneous potentials were observed in both lower extremities of 1 patient, and motor evoked potentials revealed central conduction impairment. Genetic testing identified pathogenic variants in 4 different genes, namely amyotrophic lateral sclerosis 2 (ALS2), valosin-containing protein (VCP), senataxin (SETX), and never in mitosis gene A-related kinase 1 (NEK1), in these 5 patients. Among them, 2 new variants, c.3527T>C (p.Met1176Thr) and c.1732T>C (p.Ser578Pro), were newly discovered in the ALS2 gene. Conclusion ·This article analyzes the clinical heterogeneity and genetic characteristics of SPG patients caused by ALS-related genes, providing clinical evidence for accurate diagnosis and in-depth understanding of such diseases.

Key words： spastic paraplegia; amyotrophic lateral sclerosis; ALS2; VCP; SETX; NEK1

参考文献

[1] Rimoin D L, Connor J M, Pyeritz R, et al. Emery & Rimoin's principles and practice of medical genetics[M]. New York: Churchill Livingstone, 2002.
[2] Parodi L, Fenu S, Stevanin G, et al. Hereditary spastic paraplegia: more than an upper motor neuron disease[J]. Rev Neurol, 2017, 173(5): 352-360.
[3] Fullam T, Statland J. Upper motor neuron disorders: primary lateral sclerosis, upper motor neuron dominant amyotrophic lateral sclerosis, and hereditary spastic paraplegia[J]. Brain Sci, 2021, 11(5): 611.
[4] Harding A E. Classification of the hereditary ataxias and paraplegias[J]. Lancet, 1983, 1(8334): 1151-1155.
[5] Fink J K, Heiman-Patterson T, Bird T, et al. Hereditary spastic paraplegia: advances in genetic research[J]. Neurology, 1996, 46(6): 1507-1514.
[6] Fink J K. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms[J]. Acta Neuropathol, 2013, 126(3): 307-328.
[7] Fink J K. Advances in hereditary spastic paraplegia[J]. Curr Opin Neurol, 1997, 10(4): 313-318.
[8] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
[9] Pan X Y, Dutta D, Lu S Z, et al. Sphingolipids in neurodegenerative diseases[J]. Front Neurosci, 2023, 17: 1137893.
[10] Schreij A M, Fon E A, McPherson P S. Endocytic membrane trafficking and neurodegenerative disease[J]. Cell Mol Life Sci, 2016, 73(8): 1529-1545.
[11] Berth S H, Lloyd T E. Disruption of axonal transport in neurodegeneration[J]. J Clin Invest, 2023, 133(11): e168554.
[12] Hartmann H, Ho W Y, Chang J C, et al. Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon?[J]. FEBS J, 2022, 289(24): 7688-7709.
[13] Paschen W, Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration[J]. Cell Calcium, 2005, 38(3/4): 409-415.
[14] Dubey J, Ratnakaran N, Koushika S P. Neurodegeneration and microtubule dynamics: death by a thousand cuts[J]. Front Cell Neurosci, 2015, 9: 343.
[15] Liao P L, Yuan Y C, Liu Z, et al. Association of variants in the KIF1A gene with amyotrophic lateral sclerosis[J]. Transl Neurodegener, 2022, 11(1): 46.
[16] Simone M, Trabacca A, Panzeri E, et al. KIF5A and ALS2 variants in a family with hereditary spastic paraplegia and amyotrophic lateral sclerosis[J]. Front Neurol, 2018, 9: 1078.
[17] Theuriet J, Pegat A, Leblanc P, et al. Phenoconversion from spastic paraplegia to ALS/FTD associated with CYP7B1 compound heterozygous mutations[J]. Genes, 2021, 12(12): 1876.
[18] Teyssou E, Chartier L, Amador M D, et al. Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis[J]. Neurobiol Aging, 2017, 58: 239.e11-239.e20.
[19] Kume K, Kamada M, Shimatani Y, et al. Novel monoallelic variant in ERLIN2 causes spastic paraplegia converted to amyotrophic lateral sclerosis[J]. J Neurol Sci, 2021, 430: 119984.
[20] Khosravi S, Amini E, Emamikhah M, et al. Motor neuron involvement in two ATP13A2-related families: ALS and HSP-like phenotypes[J]. Mov Disord Clin Pract, 2025, 12(6): 852-857.
[21] Clemen C S, Tangavelou K, Strucksberg K H, et al. Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases[J]. Brain, 2010, 133(10): 2920-2941.
[22] Musacchio T, Zaum A K, ü?eyler N, et al. ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia[J]. J Neurol, 2017, 264(1): 11-20.
[23] Kim J, Kim S, Nahm M, et al. ALS2 regulates endosomal trafficking, postsynaptic development, and neuronal survival[J]. J Cell Biol, 2021, 220(5): e202007112.
[24] Hadano S, Kunita R, Otomo A, et al. Molecular and cellular function of ALS2/alsin:implication of membrane dynamics in neuronal development and degeneration [J]. Neurochem Int, 2007, 51(2-4): 74-84.
[25] 朱子豪, 华冉, 姜俊红, 等. ALS2基因突变致婴儿起病型上行性遗传性痉挛性截瘫家系2例报道[J]. 中国优生与遗传杂志, 2025, 33(2): 363-372.
  Zhu Z H, Hua R, Jiang J H, et al. 2 cases of infantile ascending hereditary spastic paraplegia caused by mutation in ALS2 gene[J]. Chinese Journal of Birth Health & Heredity, 2025, 33(2): 363-372.
[26] Miceli M, Exertier C, Cavaglià M, et al. ALS2-related motor neuron diseases: from symptoms to molecules[J]. Biology, 2022, 11(1): 77.
[27] Zaki M S, Sharaf-Eldin W E, Rafat K, et al. Clinical and molecular spectrum of a large Egyptian cohort with ALS2-related disorders of infantile-onset of clinical continuum IAHSP/JPLS[J]. Clin Genet, 2023, 104(2): 238-244.
[28] Nogueira E, Alarcón J, Garma C, et al. ALS2-related disorders in Spanish children[J]. Neurol Sci, 2021, 42(5): 2091-2094.
[29] Orrell R W. ALS2-related disorder[M/OL]//Adam M P, Bick S, Mirzaa G M, et al. GeneReviews?. Seattle: University of Washington, 1993?2026[2025-09-30]. https://www.ncbi.nlm.nih.gov/books/NBK1243/.
[30] Sprute R, Jergas H, ?lmez A, et al. Genotype-phenotype correlation in seven motor neuron disease families with novel ALS2 mutations[J]. Am J Med Genet A, 2021, 185(2): 344-354.
[31] Yoganathan S, Kumar M, Aaron R, et al. Phenotype and genotype of children with ALS2 gene-related disorder[J]. Neuropediatrics, 2025, 56(1): 20-28.
[32] Weihl C C, Pestronk A, Kimonis V E. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia[J]. Neuromuscul Disord, 2009, 19(5): 308-315.
[33] de Bot S T, Schelhaas H J, Kamsteeg E J, et al. Hereditary spastic paraplegia caused by a mutation in the VCP gene[J]. Brain, 2012, 135(Pt 12): e223.
[34] Erzurumlu Y, Kose F A, Gozen O, et al. A unique IBMPFD-related P97/VCP mutation with differential binding pattern and subcellular localization[J]. Int J Biochem Cell Biol, 2013, 45(4): 773-782.
[35] Shmara A, Gibbs L, Mahoney R P, et al. Prevalence of frontotemporal dementia in females of 5 Hispanic families with R159H VCP multisystem proteinopathy[J]. Neurol Genet, 2023, 9(1): e200037.
[36] van der Zee J, Pirici D, van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His[J]. Neurology, 2009, 73(8): 626-632.
[37] de Ridder W, Azmi A, Clemen C S, et al. Multisystem proteinopathy due to a homozygous p.Arg159His VCP mutation: a tale of the unexpected[J]. Neurology, 2020, 94(8): e785-e796.
[38] Ling S C, Polymenidou M, Cleveland D W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis[J]. Neuron, 2013, 79(3): 416-438.
[39] Rudnik-Sch?neborn S, Arning L, Epplen J T, et al. SETX gene mutation in a family diagnosed autosomal dominant proximal spinal muscular atrophy[J]. Neuromuscul Disord, 2012, 22(3): 258-262.
[40] Ma L M, Shi Y Y, Chen Z C, et al. A novel SETX gene mutation associated with juvenile amyotrophic lateral sclerosis[J]. Brain Behav, 2018, 8(9): e01066.
[41] Chen X C, Chen X D, Lin X Y, et al. Unveiling ten novel SETX mutations: implications for ALS pathogenesis and clinical diversity[J]. Somatosens Mot Res, 2025: 1-8.
[42] Sberna S, Filipuzzi M, Bianchi N, et al. Senataxin prevents replicative stress induced by the Myc oncogene[J]. Cell Death Dis, 2025, 16(1): 187.
[43] Chen Y Z, Bennett C L, Huynh H M, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)[J]. Am J Hum Genet, 2004, 74(6): 1128-1135.
[44] Nguyen H P, van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD[J]. Trends Genet, 2018, 34(6): 404-423.
[45] Brenner D, Müller K, Wieland T, et al. NEK1 mutations in familial amyotrophic lateral sclerosis[J]. Brain, 2016, 139(Pt 5): e28.
[46] Riva N, Pozzi L, Russo T, et al. NEK1 variants in a cohort of Italian patients with amyotrophic lateral sclerosis[J]. Front Neurosci, 2022, 16: 833051.
Options
文章导航

/

〈 〉